Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michael Pack

Cardiovascular Disease Kalamazoo, MI Doctor of Osteopathy

NPI 1508822966 CMS profile 340793

601 John St, Suite 100, Kalamazoo, MI 49007

Open in the dashboard

General payments

$30,950

761 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michael Pack of Kalamazoo, MI is reported in the CMS Open Payments database as having received $30,950 across 761 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $5,062 74
2024 General $13,554 121
2023 General $3,239 141
2022 General $3,542 154
2021 General $1,745 108
2020 General $852 63
2019 General $2,955 100

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Pack
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Michael Pack were reported at $5,062. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Michael Pack Cardiovascular Disease median Middle half National median
2019 $2,955 $450 $127–$1,392 $163
2020 $852 $242 $77–$751 $114
2021 $1,745 $335 $101–$1,037 $132
2022 $3,542 $395 $121–$1,211 $149
2023 $3,239 $443 $136–$1,283 $160
2024 $13,554 $450 $136–$1,323 $164
2025 $5,062 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $15,226 103 payments
  2. Abbott Laboratories $6,317 52 payments
  3. Novartis Pharmaceuticals Corporation $1,606 128 payments
  4. Janssen Pharmaceuticals, Inc $1,309 128 payments
  5. E.R. Squibb & Sons, L.L.C. $1,059 98 payments
  6. Medtronic Vascular, Inc. $1,026 8 payments
  7. Pfizer Inc. $641 38 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $593 30 payments
  9. AstraZeneca Pharmaceuticals LP $503 31 payments
  10. Amgen Inc. $445 31 payments
  11. Other $2,224 114 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $13,750 4 payments
  2. Food and Beverage $11,689 729 payments
  3. Travel and Lodging $5,492 25 payments
  4. Education $18 3 payments
Products named General payments · program years 2019–2025
  1. WATCHMAN Access System $10,469 26 payments
  2. WATCHMAN $3,844 9 payments
  3. AVEIR Cardiac Rhythm Management $2,348 15 payments
  4. XARELTO $1,309 128 payments
  5. AVEIR Cardiac Rhythm Management $1,277 7 payments
  6. AVEIR Cardiac Rhythm Management $1,028 3 payments
  7. Azure $825 5 payments
  8. Cardiac Mapping System $807 6 payments
  9. ENTRESTO $801 64 payments
  10. LEQVIO $729 59 payments
  11. Other $9,052 535 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 51 drugs

Part D claims

6,012

Median for Cardiology: 2,533

Drug cost

$1,969,164

Median for Cardiology: $485,213

Branded share of claims

35.6%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 686 $759,476
Xarelto Rivaroxaban Brand 468 $499,199
Vyndamax Tafamidis Brand 12 $284,442
Entresto Sacubitril/Valsartan Brand 150 $159,269
Repatha Sureclick Evolocumab Brand 85 $87,904
Jardiance Empagliflozin Brand 59 $55,272
Metoprolol Succinate Generic 1,054 $18,974
Farxiga Dapagliflozin Propanediol Brand 18 $15,430
Flecainide Acetate Generic 258 $14,355
Praluent Pen Alirocumab Brand 14 $11,199

The 10 drugs with the highest cost, of 51 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 50 billing codes

Paid by Medicare

$89,436

Medicare's payments for the services billed

Medicare patients

1,176

Average age 75

Services billed

2,204

576 women, 600 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 52%
Atrial fibrillation 44%
Ischemic heart disease 42%
Chronic kidney disease 38%
Heart failure 37%
Diabetes 36%
Depression 29%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LEQVIO
$245 — —
CAMZYOS
$182 — —
JARDIANCE
$76 59 —
ELIQUIS
$68 686 —
ENTRESTO
$56 150 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

761 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record